Evidence map›Paper›PMID 28570576›Full record

ArticlePloS one2017

Characteristics of HIV target CD4 T cells collected using different sampling methods from the genital tract of HIV seronegative women.

Smita S Iyer, Michael J Sabula, C Christina Mehta, Lisa B Haddad, Nakita L Brown, Rama R Amara, Igho Ofotokun, Anandi N Sheth

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Smita S IyerDivision of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Michael J SabulaDivision of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
C Christina MehtaDepartment of Biostatistics, Emory University Rollins School of Public Health, Atlanta, Georgia, United States of America.
Lisa B HaddadDepartment of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Nakita L BrownDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Rama R AmaraDivision of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Igho OfotokunDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Anandi N ShethDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.ORCID http://orcid.org/0000-0002-6305-2727
Emory University · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Emory WIHS CRS - Longitudinal CohortU01AI103408 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, WINGOOD, GINA MARIA · 2013 to 2018
$14.1M
Neuro HPA Project 1U54AG062334 · NIA · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Vasiliki Michopoulos · 2018 to 2026
$12.2M
Resource for Nonhuman Primate Cell Depleting AntibodiesR24OD010976 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ENGELMAN, KATHLEEN, MAGNANI, DIOGO · 2012 to 2019
$4.7M
Emory R38 Research Training ProgramR38AI140299 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, ROUPHAEL, NADINE GEORGES · 2018 to 2021
$1.4M
Targeting CD4 TFH cells to enhance HIV vaccine-induced humoral immunityK01OD023034 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IYER, SWAMINATHAN SMITA · 2016 to 2018
$1.0M
Characterization and modulation of mucosal immunity for HIV prevention in womenK23AI114407 · NIAID · EMORY UNIVERSITY · PI SHETH, ANANDI NAYAN · 2014 to 2018
$898k
NCATS NIH HHS UL1 TR000454NIAID NIH HHS HHSN272201300031CNIAID NIH HHS K23 AI114407NIAID NIH HHS R38 AI140299NIAID NIH HHS U01 AI103408NIAID NIH HHS U24 AI126683NIA NIH HHS U54 AG062334NIH HHS K01 OD023034NIH HHS R24 OD010976
6 · The paper itself

Abstract

backgroundUnderstanding the immune profile of CD4 T cells, the primary targets for HIV, in the female genital tract (FGT) is critical for evaluating and developing effective biomedical HIV prevention strategies in women. However, longitudinal investigation of HIV susceptibility markers expressed by FGT CD4 T cells has been hindered by low cellular yield and risk of sampling-associated trauma. We investigated three minimally invasive FGT sampling methods to characterize and compare CD4 T cell yield and phenotype with the goal of establishing feasible sampling strategies for immune profiling of mucosal CD4 T cells. METHODS AND

resultsFGT samples were collected bimonthly from 12 healthy HIV negative women of reproductive age in the following order: 1) Cervicovaginal lavage (CVL), 2) two sequential endocervical flocked swabs (FS), and 3) two sequential endocervical cytobrushes (CB1, CB2). Cells were isolated and phentoyped via flow cytometry. CD4 T cell recovery was highest from each individual CB compared to either CVL or FS (p < 0.0001). The majority of CD4 T cells within the FGT, regardless of sampling method, expressed CCR5 relative to peripheral blood (p < 0.01). Within the CB, CCR5+ CD4 T cells expressed significantly higher levels of α4β7, CD69, and low levels of CD27 relative to CCR5- CD4 T cells (all p < 0.001). We also identified CD4 Treg lineage cells expressing CCR5 among CB samples.

conclusionsUsing three different mucosal sampling methods collected longitudinally we demonstrate that CD4 T cells within the FGT express CCR5 and α4β7 and are highly activated, attributes which could act in concert to facilitate HIV acquisition. FS and CB sampling methods can allow for investigation of strategies to reduce HIV target cells in the FGT and could inform the design and interpretation microbicide and vaccine studies in women.

Indexed as

HIV SeronegativityAdultCD4-Positive T-LymphocytesFemaleFlow CytometryGenitalia, FemaleHumans

Identifiers

PMID28570576
PMCPMC5453484
OpenAlexW2621019485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.